Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Blanco

Showing results (471-480 of 530) with videos related to

Pageof 53
Sort By:
The Journal of Antimicrobial Chemotherapy|March 28, 2024
Multiomics plasma effects of switching from triple antiretroviral regimens to dolutegravir plus lamivudineElisa de Lazzari, Eugenia B Negredo, Pere Domingo, et al.
AIDS (London, England)|May 11, 2018
A maintenance 3-day-per-week schedule with the single tablet regimen efavirenz/emtricitabine/tenofovir disoproxil fumarate is effective and decreases sub-clinical toxicityJhon Rojas, Jose L Blanco, Sonsoles Sanchez-Palomino, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|June 23, 2005
[Renal transplantation in patients with HIV infection]Joan-Carles Trullás, José M Miró, Guillermina Barril, et al.
The Journal of Antimicrobial Chemotherapy|May 1, 2013
Resistance to the most recent protease and non-nucleoside reverse transcriptase inhibitors across HIV-1 non-B subtypesLourdes Anta, José L Blanco, Josep M Llibre, et al.
International Journal of STD & AIDS|March 7, 2020
Maintenance of virologic suppression and improvement in comorbidities after simplification to raltegravir plus boosted darunavir among treatment-experienced HIV-infected patientsJosé L Casado, Pilar Vizcarra, José L Blanco, et al.
The Lancet. HIV|August 6, 2021
Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trialJhon Rojas, Elisa de Lazzari, Eugenia Negredo, et al.
Gastroenterology|March 26, 1999
Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adultsP Michetti, C Kreiss, K L Kotloff, et al.
The Journal of Antimicrobial Chemotherapy|March 24, 2017
Tolerability of integrase inhibitors in a real-life settingJudit Peñafiel, Elisa de Lazzari, Mireia Padilla, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|May 27, 2006
Primary human immunodeficiency virus type 1 infection: clinical, virological and immunological characteristics of 75 patients (1997-2003)Omar Sued, José M Miró, Aitor Alquezar, et al.
Infectious Diseases and Therapy|February 16, 2022
Correction to: Impact of Sexualized Substance Use and Other Risk Practices on HCV Microelimination in gbMSM Living with HIV: Urgent Need for Targeted Strategies. Results of a Retrospective Cohort StudyMaría Martínez-Rebollar, Lorena De La Mora, Miriam Campistol, et al.
Pageof 53

Showing results (471-480 of 530) with videos related to

Sort By:
Pageof 53
The Journal of Antimicrobial Chemotherapy|March 28, 2024
Multiomics plasma effects of switching from triple antiretroviral regimens to dolutegravir plus lamivudineElisa de Lazzari, Eugenia B Negredo, Pere Domingo, et al.
AIDS (London, England)|May 11, 2018
A maintenance 3-day-per-week schedule with the single tablet regimen efavirenz/emtricitabine/tenofovir disoproxil fumarate is effective and decreases sub-clinical toxicityJhon Rojas, Jose L Blanco, Sonsoles Sanchez-Palomino, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|June 23, 2005
[Renal transplantation in patients with HIV infection]Joan-Carles Trullás, José M Miró, Guillermina Barril, et al.
The Journal of Antimicrobial Chemotherapy|May 1, 2013
Resistance to the most recent protease and non-nucleoside reverse transcriptase inhibitors across HIV-1 non-B subtypesLourdes Anta, José L Blanco, Josep M Llibre, et al.
International Journal of STD & AIDS|March 7, 2020
Maintenance of virologic suppression and improvement in comorbidities after simplification to raltegravir plus boosted darunavir among treatment-experienced HIV-infected patientsJosé L Casado, Pilar Vizcarra, José L Blanco, et al.
The Lancet. HIV|August 6, 2021
Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trialJhon Rojas, Elisa de Lazzari, Eugenia Negredo, et al.
Gastroenterology|March 26, 1999
Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adultsP Michetti, C Kreiss, K L Kotloff, et al.
The Journal of Antimicrobial Chemotherapy|March 24, 2017
Tolerability of integrase inhibitors in a real-life settingJudit Peñafiel, Elisa de Lazzari, Mireia Padilla, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|May 27, 2006
Primary human immunodeficiency virus type 1 infection: clinical, virological and immunological characteristics of 75 patients (1997-2003)Omar Sued, José M Miró, Aitor Alquezar, et al.
Infectious Diseases and Therapy|February 16, 2022
Correction to: Impact of Sexualized Substance Use and Other Risk Practices on HCV Microelimination in gbMSM Living with HIV: Urgent Need for Targeted Strategies. Results of a Retrospective Cohort StudyMaría Martínez-Rebollar, Lorena De La Mora, Miriam Campistol, et al.
Pageof 53